Obseva (OBSV) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Share on StockTwits

Obseva (NASDAQ:OBSV) posted its quarterly earnings data on Thursday. The company reported ($0.42) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.04, Morningstar.com reports.

OBSV traded down $0.57 on Friday, hitting $15.35. 26,596 shares of the company traded hands, compared to its average volume of 137,080. The company has a market cap of $584.80 million, a PE ratio of -6.82 and a beta of 1.75. Obseva has a 12-month low of $9.05 and a 12-month high of $20.35.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. VHCP Management II LLC raised its stake in Obseva by 5.1% during the 2nd quarter. VHCP Management II LLC now owns 2,252,460 shares of the company’s stock valued at $34,102,000 after acquiring an additional 108,617 shares during the last quarter. FMR LLC acquired a new position in Obseva during the 2nd quarter worth approximately $27,254,000. First Manhattan Co. increased its position in Obseva by 1.6% during the 3rd quarter. First Manhattan Co. now owns 1,532,466 shares of the company’s stock worth $27,630,000 after purchasing an additional 23,500 shares during the period. Vivo Capital LLC acquired a new position in Obseva during the 2nd quarter worth approximately $14,005,000. Finally, Acuta Capital Partners LLC acquired a new position in Obseva during the 2nd quarter worth approximately $6,424,000. 68.33% of the stock is owned by hedge funds and other institutional investors.

Several analysts have commented on OBSV shares. JPMorgan Chase & Co. started coverage on Obseva in a research note on Thursday, September 13th. They set an “overweight” rating and a $29.00 price objective for the company. HC Wainwright set a $44.00 price objective on Obseva and gave the company a “buy” rating in a research note on Wednesday, August 29th. TheStreet raised Obseva from a “d+” rating to a “c-” rating in a research note on Thursday, October 11th. Wedbush set a $34.00 price objective on Obseva and gave the company a “buy” rating in a research note on Wednesday, October 3rd. Finally, Leerink Swann started coverage on Obseva in a research note on Wednesday, August 15th. They set an “outperform” rating and a $25.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $29.43.

WARNING: “Obseva (OBSV) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS” was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://weekherald.com/2018/11/10/obseva-obsv-posts-quarterly-earnings-results-beats-expectations-by-0-04-eps.html.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Read More: Swap

Earnings History for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply